BTIG Raises Guardant Health (GH) Price Target to $210
Key Points
- BTIG raised its price target for Guardant Health to $210, up from $195, on October 27, 2026.
- Guardant Health's shares recently traded around $173.25, which is about 2.9% below the closing price of $178.46 on the same day.
- The stock has a mean price target of $202.24 from 25 analysts, indicating potential upside from the recent trading level.
Get Guardant Health text alerts
We text you when insiders, Congress, analysts or big funds move on $GH.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures
On October 27, 2026, BTIG raised its price target on Guardant Health, Inc. (GH) to $210 from $195 while keeping a Buy rating. This information comes from BTIG's research note on the same date.
BTIG's adjustment reflects its ongoing confidence in Guardant Health, a precision oncology company that provides blood and tissue tests. The new target suggests a favorable outlook, considering the stock's recent price.
GH
Guardant Health, Inc.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Guardant Health
Two Sigma Investments, LP reduced its holdings by 510,061 shares, bringing its total to 3,719,301 shares valued at approximately $663.7 million. Capital International Investors also trimmed its position, selling 81,813 shares for a total of 3,399,604 shares worth about $606.7 million. Meanwhile, Deep Track Capital, LP added 55,081 shares, increasing its stake to 3,393,312 shares valued at roughly $605.6 million.
Guardant Health, Inc. Stock Holds Steady
Guardant Health's shares closed at $178.46 on October 27, 2026, while they recently traded around $173.25, about 2.9% lower. The stock is currently trading above its 50-day moving average by about 3% and significantly above its 200-day average by approximately 34.3%. However, it remains about 9.3% below its 52-week high of $191.05.
$GH price target
Guardant Health, Inc. daily closes and this analyst's $210 target. Not advice.
Recent Earnings
Guardant Health reported trailing twelve-month revenue of approximately $1.18 billion, reflecting a year-over-year growth of 44.3%. The company has a net margin of -38.3%. Its next earnings report is scheduled for November 5, 2026.
Insider Buying and Selling at Guardant Health, Inc.
Since September 16, 2026, several insiders have sold shares. Director Musa Tariq sold 116 shares at an average price of $175, totaling $20,300. Another Director, Alex M Azar II, sold 826 shares at the same average price, amounting to $144,550. Director Steve E Krognes sold 6,674 shares, totaling $1.17 million, but at an unspecified price. Additionally, on October 16, 2026, Musa Tariq sold another 116 shares at $165.88, equating to about $19,242.
Analysts Set New Price Targets
On October 27, 2026, BTIG maintained its Buy rating on Guardant Health and raised its price target to $210. Earlier, Guggenheim had a Buy rating with a target of $200, while Barclays set an Overweight rating with a target of $220. Morgan Stanley also maintained an Overweight rating with a target of $200.
About Guardant Health
Guardant Health, Inc. specializes in precision oncology, providing blood and tissue tests to help detect cancer. The company operates in the healthcare sector and is headquartered in Palo Alto, California. With a workforce of about 2,490 employees, it aims to improve cancer detection and treatment through innovative testing solutions.
Bottom Line
Investors will be watching for Guardant Health's next earnings report on November 5, 2026, for more insights into its financial health. The recent price target increase from BTIG suggests analysts are optimistic about the company's future performance.
Related Filing Alerts
Source: BTIG's rating change on $GH (Oct 27, 2026). Written by software, not financial advice. How we make alerts